Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Review
. 2016 Jul;11(7):964-75.
doi: 10.1016/j.jtho.2016.04.014. Epub 2016 Apr 23.

PD-L1 Expression in Lung Cancer

Hui Yu  1 , Theresa A Boyle  2 , Caicun Zhou  3 , David L Rimm  4 , Fred R Hirsch  5
Affiliations
Review

PD-L1 Expression in Lung Cancer

Hui Yu et al. J Thorac Oncol. 2016 Jul.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Thorac Oncol. 2017 Jan;12(1):157-159. doi: 10.1016/j.jtho.2016.11.001. J Thorac Oncol. 2017. PMID: 27988099 No abstract available.

Abstract

Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care VSports手机版. .

Keywords: Biomarker; Immunotherapy; Lung cancer; PD-L1. V体育安卓版.

PubMed Disclaimer

Conflict of interest statement

The remaining authors declare no conflict of interest.

V体育安卓版 - References

    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. - PMC - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. - VSports注册入口 - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. - PMC - PubMed

Publication types